Despite significant advances, most current in vivo models fail to fully recapitulate the biological processes that occur in humans. Here we aimed to develop an advanced humanized model with features of an organ bone by providing different bone tissue cellular compartments including preosteoblasts, mesenchymal stem/stromal (MSCs), endothelial and hematopoietic cells in an engineered microenvironment. The bone compartment was generated by culturing the human MSCs, umbilical vein endothelial cells with gelatin methacryloyl hydrogels in the center of a melt-electrospun polycaprolactone tubular scaffolds, which were seeded with human preosteoblasts. The tissue engineered bone (TEB) was subcutaneously implanted into the NSG mice and formed a morphologically and functionally organ bone. Mice were further humanized through the tail vein injection of human cord blood derived CD341 cells, which then populated in the mouse bone marrow, spleen and humanized TEB (hTEB). 11 weeks after CD341 transplantation, metastatic breast cancer cells (MDA-MB-231BO) were orthotopically injected. Cancer cell injection resulted in the formation of a primary tumor and metastasis to the hTEB and mouse organs. Less frequent metastasis and lower tumor burden were observed in hematochimeric mice, suggesting an immune-mediated response against the breast cancer cells. Overall, our results demonstrate the efficacy of tissue engineering approaches to study species-specific cancer-bone interactions. Further studies using genetically modified hematopoietic stem cells and bioengineered microenvironments will enable us to address the specific roles of signaling molecules regulating hematopoietic niches and cancer metastasis in vivo.
HIGHLIGHTS
The hTEB recapitulates features of a physiological organ bone The hTEB could attract hematopoietic and cancer cells in vivo The hTEB affects reconstitution of a hematochimeric system following CD341 injection Expression of human GM-CSF, IL-7 and IL-15, inhibit tumor growth in the hematochimeric mice Current model can serve as a platform for the development/ evaluation of new therapeutic agents Human-to-mouse xenotransplantation models have attracted much interest over the past three decades to advance our knowledge on human bone physiology and associated diseases. [1] [2] [3] Although remarkable progress has been made in improving these systems, to this end, no mouse model can adequately capture the complexity of the human bone system. In addition, the current models do not account for patient-specific confounding factors influencing the human bone admittedly in mouse experimental findings often are not supported by the results achieved from human trials.
Bone tissue engineering strategies have been well explored for basic research and modeling of certain human-specific diseases. [5] [6] [7] Moreau et al. firstly investigated the impact of tissue engineered bone (TEB) as homing site for breast cancer cell metastasis in NOD/SCID mice. 6 As with most innovative work the essential role of hematopoietic compartment of organ bone in cancer metastasis was not investigated. 6 Subsequently, Lee et al. described manufacturing of a TEB microenvironment using mesenchymal stem/stromal cells (MSC) as essential support cells of the hematopoietic stem cells (HSC) niche. Interestingly, compared with nonseeded constructs, the MSC-coated scaffolds could recruit hematopoietic progenitors in vivo in sublethally irradiated NOD-scid IL2rg null (NSG) mice. 8 Therefore, MSCs have been employed in several studies to closely replicate the morphology and structure of human tissue in vivo. 5, 9, 10 However, the humanized tissues were often replaced by endogenous mouse stromal cells after transplantation in NSG mice 10 and do not account for the complexity of bone tissue microenvironment. Indeed, bone organ contains a complex microenvironment, which is well-adapted to support multipotency and self-renewal capacities of HSC. 11 Likewise, the direct impact of osteoblast 12 and endothelial cells 13 on HSCs activation and function has been already established. Indeed, HSCs are enriched in a highly vascular endosteal region. 13 Therefore, endothelial, MSC and preosteoblast cells are the main cellular components of HSC niche. Apart from bone cellular compartments, the sponge-like geometry and structure of the extracellular matrix (ECM) also influences HSC functions. 8 Therefore, bone cellular components and ECM structure need to be taken into account to achieve a stable and successful humanization.
Recently, a TEB was exploited to study the cross-talk between cancer cells and osteoblasts. 7 Of interest, TEB resulted in re-expression of ECM molecules which had been lost in monolayer cultures. 7 A NSG mice study showed that the TEBs have potential to attract the human hematopoietic and metastatic cancer cells. 8 Although the ectopic TEB did not resemble the endogenous bone anatomy and physiology one to one, they contained the essential bone components involved in hematopoietic cell homing and cancer cell metastasis. 8 To date, different techniques have been used to fabricate scaffolds for engineering bone. 1, 14, 15 Among these, melt electrospinning writing, allows design and fabrication of biomimetic scaffolds. In recent studies by our group, tissue engineered microenvironments were used to mimic the human endosteum. 9, 14, 16 The goal of this study was to develop an advanced humanized model by providing different human bone compartments. Accordingly, human preosteoblasts (hOBs) were seeded on calcium phosphate coated medical grade poly(E-caprolactone) (PCL) scaffolds to tailor characteristic of the endosteal niche in a highly controlled fashion. In addition, the blood vessels inside the bone tissue were generated by mixing human bone marrow (BM)-derived MSC (BM-MSC) and umbilical vein endothelial cells (HUVEC) with Gelatin methacryloyl (GelMA) hydrogels in the center of tubular scaffolds. Moreover, to this end, no robust humanized model is able to investigate the species-specific homing mechanisms of human breast cancer metastasis in TEB. Current in vivo systems are often nonphysiological and/or low-throughput in nature. 8 Therefore, our second aim was to assess the capacity of our biomimetically designed humanized TEB (hTEB) to attract and retain systemically injected human hematopoietic progenitors and orthotopically injected breast cancer metastatic cells that have tropism for the bone. It has been well established that HSC transplantation is often associated with limited T-cell reconstitution, in particular when umbilical cord blood HSC are used. 17, 18 In this regards, coadministration of human cytokines has been performed to overcome the limited T cell reconstitution. 17 Thus, an engineered human breast cancer cell line capable of expressing human granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-7 (IL-7) and IL-15 in vivo was employed to overcome lack of human cytokines after HSC transplantation. 17 We hypothesized that in vivo expression of human cytokines in the hematochimeric mice could reduce tumor burden and metastasis mediated by expansion and differentiation of injected HSC toward specific cell lineages.
Materials and Methods

Ethics
All experimental protocols were carried out in accordance with the Australian Code of Practice for the Care and Use of Animals for Scientific Purposes and approved by The University of Queensland and Queensland University of Technology institutional ethics committees (ethics number: 1500000286).
Preparation of hTEB
The method has been provided in Supporting Information.
Implantation of hTEB to NSG mice
On the day of transplantation, the GelMA-based hydrogels were inserted into hOBs-seeded hollow tubular scaffold constructs
What's new?
The skeletal system is a primary site for breast cancer metastasis but no humanized mouse model can currently faithfully mimic unique niche properties of human bone. Here the authors generated a complex tissue engineered human bone (hTEB) to recapitulate hematopoietic and metastatic features of a physiological human bone. They show that the hTEB attracted hematopoietic and cancer cells in the context of a humanized mouse model. Expression of human cytokines (GM-CSF, IL-7 and IL-15) inhibited tumor growth in the hematochimeric mice, underscoring the potential for the new model to serve as a developmental platform for new therapeutic anti-cancer agents. Table S1 . The quantity and structure of bone tissue was assessed using Xray imaging (Faxitron UltraFocus 100 X-Ray System, Faxitron Bioptics) and in vivo CT imaging (Inveon; Siemens Medical Solutions, Knoxville, TN).
Tumor Immunology and Microenvironment
NSG hematopoietic xenotransplantation
Primary human cord blood CD341 cells were obtained from Lonza (purity >95%). Six week after establishment of hTEB, 1.5 3 10 5 umbilical derived CD341 cells (diluted in 150 mL of PBS) were injected intravenously via the tail vein immediately after irradiation with a sublethal dose of 2.25 Gy gamma radiation (control animals did not receive any radiation or CD341 cell injection).
Orthotopic inoculation of human breast cancer
Human MDA-MB-231BO cell line was chosen as comprises a high metastatic capacity. 17 MDA-MB-231BO cells have been generated from MDA-MB-231 cells by repeated sequential passages in nude mice, and have preferential metastasis to the bone. Here, untreated MDA-MB-231 cell are referred to as "Parental cells." Parental cells were also lentivirally transduced with PGK-GMCSF, PGK-IL7 and PGK-IL15 using three consecutive hits of transduction as previously reported 17 and here are referred to as "MDA3." Secretion of IL7, IL15 and GM-CSF was confirmed using ELISA. Eleven weeks after hTEB transplantation, the MDA-MB-231BO cell line were transplanted with parental cells (MDA-MB-231BO: parental cells; 3.6 3 10 6 : 0.4 3 10 6 ; in 50 lL PBS) or in combination with MDA3 (MDA-MB-231BO: MDA3; 3.6 3 10 6 : 0.4 3 10 6 ; in 50 lL PBS) were orthotopically injected into the forth right mammary fat pad of NSG mice (animal groups are detailed in Supporting Information Table S1 ). Tumor growth and potential metastasis to the hTEB and mouse organs were assessed via bioluminescence imaging (BLI, IVIS Spectrum 200, Perkin Elmer) after intraperitoneal injection of luciferin (200 mL; 7.5 mg/mL; PerkinElmer).
Analysis of human cell engraftment, methods for histology/immunohistochemistry and Microcomputed tomography (mCT) have been provided in Supporting Information.
Statistical analysis
Analyses were performed using Prism, v6.04 software (GraphPad). Data are expressed as mean 6 standard deviation. Groups were compared by Student t tests and 1-or 2-way ANOVA for parametric variables. Nonparametric variables were statistically analyzed by the Mann-Whitney U test. Values of p 0.05 indicated significance.
Results
In vitro characterization of hOB and generation of TEB Generation and characterization of TEB are described in Supporting Information results and (Supporting Information Figs. S1 and S2).
Establishment of humanized bone organ in NSG mice
To generate hTEB niches, GelMA hydrogels were combined with rhBMP-2 and fibrin glue, transferred into hOB-seeded scaffolds and subcutaneously transplanted into the dorsal space of NSG mice (Fig. 1a) .
Subcutaneous transplantation allows the amenability for noninvasive in vivo imaging. Bone formation was monitored using X-ray and in vivo CT imaging. At 6 week after hTEB implantation, X-ray imaging showed that the amount of calcification in the implantation site increased compared to day of transplantation (Fig. 1b) . Notably, quantification analysis showed evident bone formation after 6 weeks (6 3 10 9 6 2 3 10 9 mm
3
, Fig. 1c ).
hTEB allows multilineage reconstitution in human hematochimeric NSG mice 6 weeks after hTEB implantation, mice were conditioned using a sublethal radiation dose before human CD341 were intravenously injected (Fig. 2a) . Non-hTEB-bearing mice were considered as control mice. Human multilineage reconstitution and level of humanization were monitored in the peripheral blood (PB) of the transplanted mice by flow cytometry at Week 10 after CD341 injection (Figs. 2b and 2c). Human CD451 cells were detected in the PB of hTEBbearing (16 6 8%) and non hTEB-bearing (21 6 11%) groups with no significant difference (P 5 0.3, Fig. 2d ). Furthermore, both groups showed similar levels of multilineage reconstitution as indicated by the percentage of CD191 lymphoid cells, CD31 T cell and CD331 myeloid cells within human CD451 cells (Figs. 2e-2g).
Humanized tissue impacts on lineage differentiation of human CD341 cells in NSG mice
The impact of a humanized niche on in vivo preservation of leukemic cells has been recently reported. 19 Here, we aimed to investigate the impact of human cytokines and humanized bone tissue on humanization levels and lineage differentiation of CD341 cells following engraftment. The blood samples were aspirated in following weeks (Supporting Information Fig. S3A ). Flow cytometry analysis on PB at week 12 showed no significant difference in hCD451 levels between the hTEB bearing (12.6 6 7.6%) and control animals (7. At Week 16, PB contained similar hematochimerism (CD451) levels and proportion of CD31, CD331 and CD141 cells in hTEB bearing and control animals (Supporting Information Fig. S3D ). Of significant, the level of human B (CD191) cells in the PB of hTEB-bearing mice was significantly less than control animals in Week 16 (p < 0.05; Supporting Information Fig. S3D ). In addition, FACS analysis on PB demonstrated a 2-fold change in CD341 cells levels in hTEB bearing compared with control animals with no statistically significant levels (Supporting Information Fig. S3D ; p 5 0.08).
Mice were euthanized at Week 17 after CD341 transplantation and FACS analysis was performed on BM and spleen (Figs. 2a and 2h-2u).
BM and spleen tissues analysis showed lower percentage of CD451 cells in hTEB-bearing animals (Figs. 2h and 2o for BM and spleen, respectively), in addition FACS analysis showed the greatest expansion of human CD191 B cells (Figs. 2l and 2p, respectively) . Furthermore, subcutaneous transplantation of TEB resulted in 2-and 3-fold decrease in CD341 levels in BM and spleen respectively (Figs. 2n and 2u). Overall, CD341 cells were better preserved in PB, BM and spleen of animals, which were not bearing an hTEB. These findings suggest that hTEB might function as a niche and attract the engrafted CD341 cells. Flow cytometry analysis on spleen tissue at Week 17 showed increased levels of CD331 and CD141 cells in hTEB-bearing animals (Figs. 2r and 2s; p < 0.05).
Interestingly, the percentage of CD341 cells in BM and spleen was lower than nonbearing hTEB mice (Figs. 2n and 2u; p 5 0.8 and p < 0.05, respectively). Overall, the FACS data indicated that the presence of hTEB alters the ability of human CD341 cells to preferentially differentiate to myeloid and immature monocytes/macrophages lineages (Supporting Information Fig. S4 ), however the mechanism for this remains unknown.
Importantly, in vivo CT imaging indicated no significant difference in bone volume (BV) between human CD34-transplanted and non-transplanted hTEB-bearing mice (Supporting Information Fig. S5 ; n 20; p 5 .65) 
Primary tumor growth: Effects of in vivo expression of human GM-CSF, IL-7 and IL-15
Orthotopic tumor cell injection was performed at Week 11 after CD341 HSC injection (Fig. 1a) . Here, MDA-MB-231BO cells stably expressing luciferase (referred as MDA-MB-231BO-luc), were coinjected with a fraction of parental (MDA-MB-231) or MDA3 cells 17 in a 10 to 1 ratio. MDA3 cells are derived from parental cells by transduction with lentiviral vectors encoding for the human GM-CSF, IL7 and IL15 cytokines required for a full expansion and maturation of the human hematopoietic compartments. 17 Only MDA-MB-231BO cell express luciferase, parental and MDA3 cells do not express luciferase.
Primary tumor growth of these two cell mixes were compared in the absence or presence of human hematopoietic cells. In the no CD341 cells transplanted mice, BLI detected formation of MDA-MB-231BO-luc primary tumors in the mammary fat pad one week after tumor cell inoculation (Fig.  3a) . There was no significant difference in the BLI signal from MDA-MB-231BO cells in animals coinjected with the parental cells (2.3 3 10 7 6 2.2 3 10 7 p/sec; n 5 5) or MDA3 cells (2.7 3 10 7 6 3.4 3 10 7 p/sec; n 5 5; Mann Whitney test; p > 0.99; Fig. 3b ). Although the BLI signal significantly increased after 2 weeks, we still found no significant difference between these two groups (8.3 3 10 7 6 7.2 3 10 8 p/sec and 7.1 3 10 7 6 4.4 3 10 7 p/sec for coinjection with parental Figs. 3c and 3d) .
After 2 weeks, mice were anesthetized and the tumors harvested. Though co-injection with MDA3 resulted in reduced tumor weight and volume compared with the mix with the parental cell line in the nonhematochimeric groups, the difference was nonsignificant (n 5 5; p 5 0.15; Figs. 3e and 3f). On the contrary, humanization of the blood system resulted in a significant decrease in tumor weight (p < 0.05) and volume (p < 0.05) where MDA-MB-231BO-luc cells were coinjected with MDA3 (n 5 5; Figs. 3e and 3f) .
In addition, antihuman CD45 antibody staining confirmed higher migration of human CD451 cell toward the primary tumor when MDA-MB-231BO-luc cells were coinjected with MDA3 (Fig. 4) . Altogether, these results confirmed that engineering of MDA-MB-231 breast cancer cells to express human cytokines (GM-CSF, IL-7 and IL-15) can significantly inhibit tumor growth in hematochimeric mice.
Tumor conditioning and secretion of human cytokines affect the ability of human CD341 cells to reconstitute a multilineage hematochimeric system in NSG mice A number of studies employed stem cell transplantation for breast cancer therapy through promoting antitumor immunity. 17, 20 In this regards, immunotherapeutic approaches have shown promising results. 17, 21 Thus, we investigated the impact of tumor formation and secretion of human cytokines on the reconstitution of a hematochimeric system in NSG mice. Flow cytometry analysis on PB at Week 12 and 14 showed similar level of CD451 cells in animals challenged with MDA-MB-231BO-luc 1 parental cells and MDA-MB-231BO-luc 1 MDA3 (p 5 0.19; one-way ANOVA; data not shown). Furthermore, flow cytometry analysis indicated no difference in the proportion of human CD31, and CD341 cells in the PB at 12 weeks. Interestingly, cancer cell injection resulted in a significant reduction of human CD191 cells levels with the greatest reduction following co-injection with MDA3 (one-way ANOVA; p < 0.0001; data not shown). The levels of human CD331 and CD141 cells were significantly increased upon tumor inoculation as expected due to the high levels of endogenous G-CSF secreted by MDA3 cells 17 (one-way ANOVA; p < 0.0001; data not shown). In this study, the tumor was removed at Week 13, thus removing the source of human cytokines in the following weeks (Fig. 5a) .
FACS analysis was performed on PB (Week 16) and BM, and spleen (Week 17) (Fig. 5b) . FACS analysis on PB at Week 16 showed marginally higher hematochimerism (human CD451 percentage) in tumor inoculated mice ( Fig.  5c ; p 5 0.3), however the level of CD191 cells in tumor inoculated mice was significantly less than mice which only received hTEB and CD341 cells transplantation ( Fig. 5c ; p < 0.05). In addition, tumor conditioning resulted in significant increase in levels of CD331 and CD141 cells ( Fig. 5c ; p < 0.01 and p < 0.05, respectively).
BM analysis in MDA-MB-231BO-luc inoculated animals displayed fewer human CD191 cells compared with control (no cancer cell injection) with much lower difference in MDA3 injected animals ( Fig. 5d ; p < 0.05). Statistical analysis showed no significant differences in levels of CD31, CD141 and CD341 ( Fig. 5d; p 5 0.3) .
Nevertheless, we could observe lower levels of CD331 cells in the spleen of mice, which challenged with MDA-MB-231BO-luc cells in both groups ( Fig. 5d ; p < 0.05). This suggests that CD341 cells can be induced along the myeloid or lymphoid lineages depending on extrinsic cues. While challenge with cancer cells resulted in increased percentage of CD141 in spleen, the level of CD341 was almost negligible (between 0.4 and 1.3%) with no significant difference among groups ( Fig. 5e; p 5 0.3) . Infiltration of human CD451 cells in the mouse organs, such as the lung, spleen and femur was confirmed using immunostaining for human CD451 cells (Supporting Information  Fig. S6 ). Altogether, tumor conditioning and human cytokine expression affect the ability of human CD341 cells to reconstitute a multilineage hematochimeric system in NSG mice (Supporting Information Fig. S7 ).
hTEB could recruit breast cancer metastatic cells in NSG mice
Upon hTEB transplantation, we observed that newly formed bone tissue was able to recapitulate the radiographic features of a physiological organ bone (Figs. 1b and 1c) . Here, the BV was measured before and after cancer cell inoculation using in vivo CT imaging. Notably, we observed no difference in BV after injection of cancer cell with parental or MDA3 cell lines (Fig. 6a ).
Breast cancer cells are able to metastasize from the primary tumor and colonize in many different organs, and almost 60-85% of patients with metastatic breast cancer harbor bone metastases. 22 We hence investigated the metastasis of cancer cells from the primary tumor to anatomically distant organs, including the hTEB. Breast cancer cell metastasis to the hTEB was observed at Week 6 after tumor inoculation (Figs. 6b and  6c ). In the absence of CD341 cells, coinjection of MDA-MB-231BO-luc with MDA3 showed improved metastasis to hTEB (75%, n 5 14). Of interest, hematochimerism resulted in reduced levels of metastasis to hTEB by MDA-MB-231BO-luc cell, irrespective of coinjection with parental or MDA3 (14%; Fig. 6b and 6c; n 5 28) . Thus, hTEB can be utilized as a platform to recruit metastatic tumor cells in vivo.
The lung is the most frequent site of metastasis in both preclinical models and patients. 23 As expected, our investigation showed metastasis to the lung in all nonhematochimeric mice (n 5 9), in contrast coinjection of parental and MDA3 cells resulted in 85 and 71% lung metastasis in hematochimeric mice, respectively ( Fig. 6d and Supporting Information Fig. S8 ; n 5 14). Cancer cell metastasis was confirmed by positive staining for Lamin A/C and Von Willebrand Factor antibodies in lung tissue (Supporting Information Fig. S8 ). Metastasis to liver was present in all and 80% of nonhematochimeric mice inoculated with MDA3 and parental cells, respectively ( Fig. 6d ; n 5 9). Hematochimerism resulted in reduced metastasis to liver with lowest percentage in the parental Group (57%; n 5 7). Increasing clinical evidence unveils the existence of premetastatic niches in sentinel lymph nodes in samples harvested from breast cancer patients. 23 Therefore, we considered the possibility of metastasis to lymph nodes and observed metastasis to 100 and 40% of nonhematochimeric mice in MDA3 and parental groups respectively (n 5 9), however no metastasis to the lymph nodes was observed in hematochimeric mice ( Fig.  6d; n 5 14) . Altogether, we established a hematochimerism in an autologous model of breast cancer with reduced levels of metastatic spread to frequent metastatic sites (Supporting Information Fig. S9) . Lastly, the hTEB were analysed ex vivo using quantitative mCT and the newly formed organ bone recapitulated the features of a physiological bone with a cortex-like outer structure (Fig. 6e) . Ex vivo mCT analysis confirmed in vivo CT imaging and there was no significant difference in BV between hematochimeric and control (no CD341 cell injection) groups (Fig. 6f) .
The hTEB recapitulates morphological characteristics of a physiological organ bone
From a gross morphology point of view, the hTEB appeared well vascularized and well connected into the surrounding tissue without any fibrous encapsulation (Fig. 7a) . Notably, H&E staining showed that the hTEB was well-vascularized and could recapitulate the morphologic features of organ bone with both trabecular bone and hematopoietic regions (Fig. 7b) . The hematopoietic compartment contained sinusoids which were filled with erythrocytes and other hematopoietic cells. The bone region was stained for Safranin O (Fig. 7c) and human collagen type-I antibody which revealed that most of the bone ECM was of human origin (Fig. 7d) . Immunostaining with Lamin A/C antibody confirmed the human origin of cells inside the bone and hematopoietic regions (Fig. 7e) . To investigate the recruitment of human hematopoietic cells into the hTEB, sections were stained with human-specific CD45 antibody, a common hematopoietic cell marker (Fig. 7f) . This confirmed the recruitment of human hematopoietic cells into the hTEB. Lastly, immunostaining with mouse specific CD31 antibody, a key endothelial cell marker, demonstrated vascularization of the hTEB (Fig. 7g) . Altogether, our results showed generation of humanized bone structures which recapitulate, in part, the morphologic features of functional human bone.
Discussion
Animal models are often used in preclinical experiments to investigate the effectiveness and safety of new therapeutical agents before moving forward into human clinical trials. However, in order to be a clinically relevant investigative tool, these models need to represent the human physiological and pathological conditions with high fidelity. In this regard, humanized mouse models, with a full representation of the human immune system, has become a valuable research tool for cancer studies to test new therapies. Based on these concepts, we have established an original humanized mouse model, which has both human bone tissue and human immune cells. This system could further replicate human breast cancer metastasis to the human bone in the presence of human immune cells.
The crucial role of osteoblastic/osteoprogenitor cells as the main cellular component of the HSC niche has been well documented. 12, 24, 25 Accordingly, transplantation of skeletal progenitors revealed generation of a hematopoietic microenvironment upon ectopic transplantation in mice. 24 To the best of our knowledge, despite phenotypical evidence confirming individual impacts of endothelial, mesenchymal and osteoblastic cells on HSCs functions, engineering of a human bone organ hosting all cellular compartment of HSC niche has not yet been achieved. Indeed, vascularization is crucial when engineering tissue for in vivo transplantation. In this regard, prevascularization approaches have been applied for introducing vasculature into engineered tissues. 26, 27 Here, we assessed the feasibility of generating prevascularized tissues by use of scaffold-based and cell-based strategies. HUVEC and MSC were cocultured in GelMA, which can serve as a niche for survival of transplanted cells as well as infiltration of host endothelial cells 28 and vascularization within the developing bone organ. In vivo, pericytes contribute to stabilizing the newly formed vasculature; therefore, cotransplantation of MSC together with endothelial cells has been used to enhance the engraftment and capillary formation potential of endothelial cells. 29 The primary role of BMP for functional in vivo bone regeneration has been confirmed before. 2, 30 We have shown, in the absence of BMP, scaffolds were largely composed of fibrotic tissue that established a low level of hematopoietic cell recruitment. 31 X-ray and mCT analyses confirmed the bone formation in BMP transplanted groups. 31 Although several studies reported the development of humanized bone for cancer research, the immune system in current humanized mouse models depended profoundly on the host's immune system. 6, 8, 32, 33 Bone and immune system are intimately linked together, as the organ bone regulates development of immune cells. The significance of the immune system in the pathogenesis of bone metastases has been widely demonstrated. 34, 35 Therefore, it is important to generate a system that faithfully recapitulates the disease. To assess whether the humanized BM niche can affect human haematopoiesis, CD341 cell were intravenously injected into hTEB-bearing mice. PB engraftment was validated 10 weeks after injection. As a result, CD341 cells gave rise to various lineages of blood cells in the PB at Week 12, with no difference between control and hTEB bearing animals. There was a reduction in hematopoietic frequencies not only in the PB of hTEB-bearing mice, but also in BM and spleen. Of interest, the frequency of CD331 (myeloid) and CD141 (monocytes) cells was increased in PB and BM of hTEB transplanted mice (Fig. 2, Supporting Information  Fig. S4 ). Additionally the levels of CD341 cells in BM of hTEB-bearing animals were significantly reduced, suggesting that humanized tissue could recruit some of the hematopoietic progenitor cells. In agreement with our findings, Lee et al. described lower frequencies of endogenous hematopoietic progenitors in MSC-seeded scaffolds, with no differences in frequencies of immune cells in scaffold implanted mice. 8 Furthermore, T cell population in the whole lymphocyte population were reported to be low, 8 and here low levels of CD451 cells were seen to be CD31. Overall, we suggest that the hTEB can attract hematopoietic progenitors and develop an equilibrium state similar to the native bone that does not affect overall PB cell ratios. To the best of our knowledge, no comprehensive experimental research exists investigating the impact of a humanized TEB on humanized immune system following HSC transplantation. Here, we attempted to answer the question of how humanized bone shapes the humanized immune system in PB, BM and spleen. However, full characterization of recruited hematopoietic cells to the hTEB as well as further characterization of myeloid and lymphoid cells awaits further investigation. Mechanistically, it has been suggested that secretion and release of specific cytokines such as IL-6, and VEGF, from the seeded cells into the surrounding environment can enhance the vascularization and recruitment of progenitors to the hTEB 8 ; however, a full analysis of the HSC homing mechanism is required. Therefore, growth factor-loaded scaffolds and administration of genetically modified HSC are recommended.
Further discussion on impacts of human cytokines on HSC differentiation is provided in Supporting Information.
We observed recruitment of metastatic breast cancer cells to the hTEB. It has been well-documented that organs of future metastasis selectively and actively recruit the circulating tumor cells. 23, 36, 37 In this regards, BMP-2 not only permits the in situ BM genesis, but also showed the capacity for bone metastasis. 2, 30, 32 Moreau et al. reported that BMP-2 loaded scaffolds could function as a homing site for metastatic breast cancer. 6 BMP-2 is expressed on prostate cancer cells with established bone metastases and BMP-2 effects on the process of metastasis has been observed. 32 More recently, the potential of BMP-2 functionalized scaffolds to serve as a surrogate niche for breast cancer metastases has been confirmed in a human xenograft model by cancer cell injection in rotator cuff. 30 We injected cancer cells into the mammary fat pad, to physically separate the hTEB from the primary tumor site and to serve as a more biologically relevant orthotopic model to obtain clinically relevant information, as breast cancer implanted in different sites have different gene signatures. 38 Altogether, our humanized tissue is able to attract metastatic breast cancer cells, enabling the study of cancer metastasis. However, some limitations of our study need to be considered. First of all, the impact of human cytokines on hematopoietic progenitors was investigated in the tumor conditioning, thus the cytokines' effects on CD341 cells in the presence of hTEB without tumor needs to be investigated. Second, further studies in the presence of chemotherapeutic drugs and other hematopoietic cytokines, together with higher CD341 cell numbers are now indicated as in vivo engineered bone-like organs remain in the center of preclinical animal model development. This current approach provides a simple yet robust model to generate a humanized organ bone, which enables future studies of cancer metastasis to the bone. By selectively manipulating the hTEB, we may be able to either increase or suppress the cancer cell metastasis to the humanized bone to dissect the molecular mechanisms behind cancer metastasis.
Conclusion
The lack of relevant in vivo models of breast cancer metastasis to bone poses a major problem for the research and clinical community. Here, we report the development of an original humanized mouse model containing both a humanized bone organ and a humanized immune system. We conceive that such humanized mouse models can be used as a preclinical research tool which potentially enable mechanistic investigation of HSC homing and studies of breast cancer metastasis to bone.
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